Using Pentoxifylline and Celecoxib to treat Parkinson's disease
Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
This study is testing whether the medications Pentoxifylline and Celecoxib can help improve symptoms for adults with Parkinson's disease who are already taking carbidopa-levodopa.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Mansoura) |
| Trial ID | NCT05962957 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Pentoxifylline and Celecoxib on patients diagnosed with Parkinson's disease. The study aims to assess the potential benefits of these medications in managing both motor and non-motor symptoms associated with the disease. Participants will receive carbidopa-levodopa along with the study medications to evaluate their effectiveness in improving overall patient outcomes. The trial will include adults aged 18 and older who meet specific diagnostic criteria for Parkinson's disease.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with Parkinson's disease.
Not a fit: Patients with significant liver and kidney function abnormalities or those with known allergies to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new treatment options that improve the quality of life for patients with Parkinson's disease.
How similar studies have performed: While the specific combination of Pentoxifylline and Celecoxib in this context is novel, previous studies have explored the role of anti-inflammatory agents in Parkinson's disease with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale. Exclusion Criteria: * Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications
Where this trial is running
Mansoura
- Faculty of Medicine, Mansoura University — Mansoura, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.